Try a new search

Format these results:

Searched for:

in-biosketch:true

person:loebs01

Total Results:

491


Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing

Leader, Amy E; Rebbeck, Timothy R; Oh, William K; Patel, Alpa V; Winer, Eric P; Bailey, LeeAnn O; Gomella, Leonard G; Lumpkins, Crystal Y; Garraway, Isla P; Aiello, Lisa B; Baskin, Monica L; Cheng, Heather H; Cooney, Kathleen A; Ganzak, Amanda; George, Daniel J; Halabi, Susan; Hathaway, Feighanne; Healy, Claire; Kim, Joseph W; Leapman, Michael S; Loeb, Stacy; Maxwell, Kara N; McNair, Christopher; Morgan, Todd M; Prindeville, Breanne; Soule, Howard R; Steward, Whitney L; Suttiratana, Sakinah C; Taplin, Mary-Ellen; Yamoah, Kosj; Fortune, Thierry; Bennett, Kris; Blanding-Godbolt, Joshua; Gross, Laura; Giri, Veda N
BACKGROUND:Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-engagement of Black males in PCA GT, limiting the benefit of precision therapy and tailored cancer screening despite longstanding awareness of these disparities. To address these critical disparities, the Socioecological Model (SEM) was employed to develop comprehensive recommendations to overcome barriers and implement equitable strategies to engage Black males in PCA GT. METHODS:Clinical/research experts, national organization leaders, and community stakeholders spanning multiple regions in US and Africa participated in developing a framework for equity in PCA GT grounded in the SEM. A novel mixed-methods approach was employed to generate key areas to be addressed and informed statements for consensus consideration utilizing the modified Delphi model. Statements achieving strong consensus (> =75% agreement) were included in final equity frameworks addressing clinical/community engagement and research engagement. RESULTS:All societal levels of the SEM (interpersonal, institutional, community, and policy/advocacy) must deliver information about PCA GT to Black males that address benefits/limitations, clinical impact, hereditary cancer implications, with acknowledgment of mistrust (mean scores [MS] 4.57-5.00). Interpersonal strategies for information delivery included engagement of family/friends/peers/Black role models to improve education/awareness and overcome mistrust (MS 4.65-5.00). Institutional strategies included diversifying clinical, research, and educational programs and integrating community liaisons into healthcare institutions (MS 4.57-5.00). Community strategies included partnerships with healthcare institutions and visibility of healthcare providers/researchers at community events (MS 4.65-4.91). Policy/advocacy included improving partnerships between advocacy and healthcare/community organizations while protecting patient benefits (MS 4.57-5.00). Media strategies were endorsed for the first time at every level (MS 4.56-5.00). CONCLUSION/CONCLUSIONS:The SEM-based equity frameworks proposed provide the first multidisciplinary strategies dedicated to increase engagement of Black males in PCA GT, which are critical to reduce disparities in PCA-mortality through informing tailored screening, targeted therapy, and cascade testing in families.
PMCID:11409532
PMID: 39289635
ISSN: 1471-2458
CID: 5738702

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review

Cheng, Heather H; Shevach, Jeffrey W; Castro, Elena; Couch, Fergus J; Domchek, Susan M; Eeles, Rosalind A; Giri, Veda N; Hall, Michael J; King, Mary-Claire; Lin, Daniel W; Loeb, Stacy; Morgan, Todd M; Offit, Kenneth; Pritchard, Colin C; Schaeffer, Edward M; Szymaniak, Brittany M; Vassy, Jason L; Katona, Bryson W; Maxwell, Kara N
IMPORTANCE/UNASSIGNED:Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration-approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs. OBSERVATIONS/UNASSIGNED:This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males. CONCLUSIONS AND RELEVANCE/UNASSIGNED:Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.
PMID: 39052257
ISSN: 2374-2445
CID: 5696072

Plant-based diets, animal agriculture, and the connection with urological and planetary health

Gupta, Natasha; Leapman, Michael S; Loeb, Stacy
PURPOSE OF REVIEW/OBJECTIVE:We summarize the latest evidence regarding the impact of plant-based diets on urological and planetary health to facilitate patient counseling and research regarding dietary intervention. RECENT FINDINGS/RESULTS:Studies have highlighted the association of plant-based diets with a lower risk of multiple urological conditions including prostate cancer, erectile dysfunction, benign prostatic hyperplasia, and nephrolithiasis, as well as benefits for planetary health. SUMMARY/CONCLUSIONS:Plant-based diets are associated with numerous benefits that co-promote urological and planetary health.
PMCID:11303101
PMID: 38832408
ISSN: 1473-6586
CID: 5738582

PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer

Englman, Cameron; Maffei, Davide; Allen, Clare; Kirkham, Alex; Albertsen, Peter; Kasivisvanathan, Veeru; Baroni, Ronaldo Hueb; Briganti, Alberto; De Visschere, Pieter; Dickinson, Louise; Gómez Rivas, Juan; Haider, Masoom A; Kesch, Claudia; Loeb, Stacy; Macura, Katarzyna J; Margolis, Daniel; Mitra, Anita M; Padhani, Anwar R; Panebianco, Valeria; Pinto, Peter A; Ploussard, Guillaume; Puech, Philippe; Purysko, Andrei S; Radtke, Jan Philipp; Rannikko, Antti; Rastinehad, Art; Renard-Penna, Raphaele; Sanguedolce, Francesco; Schimmöller, Lars; Schoots, Ivo G; Shariat, Shahrokh F; Schieda, Nicola; Tempany, Clare M; Turkbey, Baris; Valerio, Massimo; Villers, Arnauld; Walz, Jochen; Barrett, Tristan; Giganti, Francesco; Moore, Caroline M
BACKGROUND AND OBJECTIVE/OBJECTIVE:The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting of prostate magnetic resonance imaging (MRI) in patients on active surveillance (AS) for prostate cancer. An international consensus group recently updated these recommendations and identified the areas of uncertainty. METHODS:A panel of 38 experts used the formal RAND/UCLA Appropriateness Method consensus methodology. Panellists scored 193 statements using a 1-9 agreement scale, where 9 means full agreement. A summary of agreement, uncertainty, or disagreement (derived from the group median score) and consensus (determined using the Interpercentile Range Adjusted for Symmetry method) was calculated for each statement and presented for discussion before individual rescoring. KEY FINDINGS AND LIMITATIONS/UNASSIGNED:Participants agreed that MRI scans must meet a minimum image quality standard (median 9) or be given a score of 'X' for insufficient quality. The current scan should be compared with both baseline and previous scans (median 9), with the PRECISE score being the maximum from any lesion (median 8). PRECISE 3 (stable MRI) was subdivided into 3-V (visible) and 3-NonV (nonvisible) disease (median 9). Prostate Imaging Reporting and Data System/Likert ≥3 lesions should be measured on T2-weighted imaging, using other sequences to aid in the identification (median 8), and whenever possible, reported pictorially (diagrams, screenshots, or contours; median 9). There was no consensus on how to measure tumour size. More research is needed to determine a significant size increase (median 9). PRECISE 5 was clarified as progression to stage ≥T3a (median 9). CONCLUSIONS AND CLINICAL IMPLICATIONS/CONCLUSIONS:The updated PRECISE recommendations reflect expert consensus opinion on minimal standards and reporting criteria for prostate MRI in AS.
PMID: 38556436
ISSN: 1873-7560
CID: 5689562

Readability Assessment of Patient Education Materials on Uro-oncological Diseases Using Automated Measures

Rodler, Severin; Maruccia, Serena; Abreu, Andre; Murphy, Declan; Canes, David; Loeb, Stacy; Malik, Rena D; Bagrodia, Aditya; Cacciamani, Giovanni E
BACKGROUND AND OBJECTIVE/OBJECTIVE:Readability of patient education materials is of utmost importance to ensure understandability and dissemination of health care information in uro-oncology. We aimed to investigate the readability of the official patient education materials of the European Association of Urology (EAU) and American Urology Association (AUA). METHODS:Patient education materials for prostate, bladder, kidney, testicular, penile, and urethral cancers were retrieved from the respective organizations. Readability was assessed via the WebFX online tool for Flesch Kincaid Reading Ease Score (FRES) and for reading grade levels by Flesch Kincaid Grade Level (FKGL), Gunning Fog Score (GFS), Smog Index (SI), Coleman Liau Index (CLI), and Automated Readability Index (ARI). Layperson readability was defined as a FRES of ≥70 and with the other readability indexes <7 according to European Union recommendations. This study assessed only objective readability and no other metrics such as understandability. KEY FINDINGS AND LIMITATIONS/UNASSIGNED:Most patient education materials failed to meet the recommended threshold for laypersons. The mean readability for EAU patient education material was as follows: FRES 50.9 (standard error [SE]: 3.0), and FKGL, GFS, SI, CLI, and ARI all with scores ≥7. The mean readability for AUA patient material was as follows: FRES 64.0 (SE: 1.4), with all of FKGL, GFS, SI, and ARI scoring ≥7 readability. Only 13 out of 70 (18.6%) patient education materials' paragraphs met the readability requirements. The mean readability for bladder cancer patient education materials was the lowest, with a FRES of 36.7 (SE: 4.1). CONCLUSIONS AND CLINICAL IMPLICATIONS/CONCLUSIONS:Patient education materials from leading urological associations reveal readability levels beyond the recommended thresholds for laypersons and may not be understood easily by patients. There is a future need for more patient-friendly reading materials. PATIENT SUMMARY/RESULTS:This study checked whether health information about different cancers was easy to read. Most of it was too hard for patients to understand.
PMID: 39048402
ISSN: 2405-4569
CID: 5738652

Phosphorus Content of Several Plant-Based Yogurts

Babich, John S; Patel, Jason; Dupuis, Léonie; Goldfarb, David S; Loeb, Stacy; Borin, James; Joshi, Shivam
OBJECTIVE:In people with chronic kidney disease (CKD), hyperphosphatemia is a risk factor for mortality. Though unproven, dietary phosphorus control is considered essential in CKD. Although dietary and serum phosphorus are correlated, phosphorus from plant foods rich in phytate is less bioavailable than from animal and processed foods. Yogurt, valued for its low phosphorus and high protein, may be detrimental in CKD due to animal protein content. Plant-based yogurts (PBYs) might offer similar benefits without the downsides of animal protein, but little is known about their phosphorus content. DESIGN AND METHODS/METHODS:Protein contents and phosphorus additives were gathered from nutrition labels of several PBYs, including almond, cashew, oat, coconut, and soy substrates. Phosphorus content was measured via emission spectrometry by Eurofins (Madison, WI), and the phosphorus-to-protein ratio (PPR) was calculated for each PBY. RESULTS:Phosphorus content was highest in Silk Soy Strawberry, Silk Almond Strawberry, and Siggi's Coconut Mixed Berries, while it was lowest in So Delicious Coconut Strawberry, Oatly Oat Strawberry, Forager Cashew Strawberry, and Kite Hill Almond Strawberry. Ingredient labels revealed that Silk Soy Strawberry, Silk Almond Strawberry, and Oatly Oat Strawberry contained phosphorus additives, and Siggi's Coconut Mixed Berries contained pea protein additives. Though from the same substrate class, So Delicious Coconut Strawberry and Siggi's Coconut Mixed Berries showed significant differences in phosphorus and protein contents. All seven PBYs had higher PPR ratios than dairy yogurts like Stonyfield Organic Oikos Strawberry, Chobani Nonfat Strawberry, and Yoplait Greek Strawberry. CONCLUSION/CONCLUSIONS:Low-PPR foods are important for CKD patients. Siggi's Coconut Mixed Berries had the lowest PPR, making it potentially the most desirable for CKD patients. However, there is high variability in PPR among PBYs with the same substrate; therefore, Delicious Coconut Strawberry had the highest PPR, highlighting the importance of product selection for patients with CKD.
PMID: 38992517
ISSN: 1532-8503
CID: 5732452

Readability and Information Quality in Cancer Information From a Free vs Paid Chatbot

Musheyev, David; Pan, Alexander; Gross, Preston; Kamyab, Daniel; Kaplinsky, Peter; Spivak, Mark; Bragg, Marie A; Loeb, Stacy; Kabarriti, Abdo E
IMPORTANCE/UNASSIGNED:The mainstream use of chatbots requires a thorough investigation of their readability and quality of information. OBJECTIVE/UNASSIGNED:To identify readability and quality differences in information between a free and paywalled chatbot cancer-related responses, and to explore if more precise prompting can mitigate any observed differences. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:This cross-sectional study compared readability and information quality of a chatbot's free vs paywalled responses with Google Trends' top 5 search queries associated with breast, lung, prostate, colorectal, and skin cancers from January 1, 2021, to January 1, 2023. Data were extracted from the search tracker, and responses were produced by free and paywalled ChatGPT. Data were analyzed from December 20, 2023, to January 15, 2024. EXPOSURES/UNASSIGNED:Free vs paywalled chatbot outputs with and without prompt: "Explain the following at a sixth grade reading level: [nonprompted input]." MAIN OUTCOMES AND MEASURES/UNASSIGNED:The primary outcome measured the readability of a chatbot's responses using Flesch Reading Ease scores (0 [graduate reading level] to 100 [easy fifth grade reading level]). Secondary outcomes included assessing consumer health information quality with the validated DISCERN instrument (overall score from 1 [low quality] to 5 [high quality]) for each response. Scores were compared between the 2 chatbot models with and without prompting. RESULTS/UNASSIGNED:This study evaluated 100 chatbot responses. Nonprompted free chatbot responses had lower readability (median [IQR] Flesh Reading ease scores, 52.60 [44.54-61.46]) than nonprompted paywalled chatbot responses (62.48 [54.83-68.40]) (P < .05). However, prompting the free chatbot to reword responses at a sixth grade reading level was associated with increased reading ease scores than the paywalled chatbot nonprompted responses (median [IQR], 71.55 [68.20-78.99]) (P < .001). Prompting was associated with increases in reading ease in both free (median [IQR], 71.55 [68.20-78.99]; P < .001)and paywalled versions (median [IQR], 75.64 [70.53-81.12]; P < .001). There was no significant difference in overall DISCERN scores between the chatbot models, with and without prompting. CONCLUSIONS AND RELEVANCE/UNASSIGNED:In this cross-sectional study, paying for the chatbot was found to provide easier-to-read responses, but prompting the free version of the chatbot was associated with increased response readability without changing information quality. Educating the public on how to prompt chatbots may help promote equitable access to health information.
PMCID:11282443
PMID: 39058491
ISSN: 2574-3805
CID: 5738662

ChatGPT can help guide and empower patients after prostate cancer diagnosis

Collin, Harry; Keogh, Kandice; Basto, Marnique; Loeb, Stacy; Roberts, Matthew J
BACKGROUND/OBJECTIVES/OBJECTIVE:Patients often face uncertainty about what they should know after prostate cancer diagnosis. Web-based information is common but is at risk of being of poor quality or readability. SUBJECTS/METHODS/METHODS:We used ChatGPT, a freely available Artificial intelligence (AI) platform, to generate enquiries about prostate cancer that a newly diagnosed patient might ask and compared to Google search trends. Then, we evaluated ChatGPT responses to these questions for clinical appropriateness and quality using standardised tools. RESULTS:ChatGPT generates broad and representative questions, and provides understandable, clinically sound advice. CONCLUSIONS:AI can guide and empower patients after prostate cancer diagnosis through education. However, the limitations of the ChatGPT language-model must not be ignored and require further evaluation and optimisation in the healthcare field.
PMID: 38926606
ISSN: 1476-5608
CID: 5733192

Correction: Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts

Scott, Colin; Campbell, Peter; Nemirovsky, Amy; Loeb, Stacy; Malik, Rena
PMID: 37749168
ISSN: 1476-5608
CID: 5725252

'It Just Makes Sense to Me': A qualitative study exploring patient decision-making and experiences with prostate MRI during active surveillance for prostate cancer

Sutherland, Ryan; Gross, Cary P; Ma, Xiaomei; Jeong, Farah; Seibert, Tyler M; Cooperberg, Matthew R; Catalona, William J; Ellis, Shellie D; Loeb, Stacy; Schulman-Green, Dena; Leapman, Michael S
INTRODUCTION/UNASSIGNED:Although prostate magnetic resonance imaging (MRI) is commonly used in the diagnosis, staging and active surveillance of prostate cancer, little is known about patient perspectives on MRI. METHODS/UNASSIGNED:We performed a qualitative study consisting of in-depth, semi-structured interviews of patients with low- and intermediate-risk prostate cancer managed with active surveillance. Interviews focused on experiences with and knowledge of prostate MRI and MRI-ultrasound fusion biopsy during active surveillance. We purposively sampled patients who received prostate MRI as part of their clinical care, conducted interviews until reaching thematic saturation and performed conventional content analysis to analyse data. RESULTS/UNASSIGNED:Twenty patients aged 51-79 years (mean = 68 years) participated in the study. At diagnosis, 17 (85%) had a Gleason grade group 1, and three (15%) had a grade group 2 tumour. Overall, participants viewed prostate MRI as a valuable tool that accurately localizes and monitors prostate cancer over time, and they considered prostate MRI central to active surveillance monitoring. We identified five thematic categories related to MRI use: (1) the experiential aspects of undergoing an MRI scan; (2) the experience of visualizing one's own prostate and prostate cancer; (3) adequacy of provider explanations of MRI results; (4) confidence in prostate MRI in decision-making; and (5) the role of prostate MRI in longitudinal follow-up, including an interest in using MRI to modify the timing of, or replace, prostate biopsy. CONCLUSION/UNASSIGNED:Patients value prostate MRI as a tool that enhances their confidence in the initial diagnosis and monitoring of prostate cancer. This work can inform future studies to optimize patient experience, education and counselling during active surveillance for prostate cancer.
PMCID:11168777
PMID: 38873351
ISSN: 2688-4526
CID: 5669442